Celgene
February 4, 2019
[vc_row][vc_column][vc_column_text] Cell and gene therapies (CGTs) offer an unprecedented opportunity to treat diseases for which existing interventions are inadequate, potentially offering cures for previously terminal illnesses. […]
August 31, 2017
[vc_row][vc_column][vc_column_text] Gilead Sciences has ended its M&A moratorium with an $11.9B all-cash acquisition of CAR-T Cell Therapy pioneers Kite Pharma. Kite’s leading drug Axi-Cel is expected […]
August 23, 2016
Pharmaceutical giants Pfizer are expanding their cancer portfolio through the $14B acquisition of California-based biopharmaceutical company Medivation. The acquisition follows two recent unsuccessful bids for Medivation […]
June 27, 2016
Australian Regenerative Medicine company Mesoblast recently suffered a significant financial setback in the ongoing development of MPC-150-IM, their experimental Phase III treatment for chronic heart failure, […]
July 1, 2015
Celgene and Juno Therapeutics have announced a decade long collaboration to advance potentially groundbreaking immunotherapies for patients with cancer and autoimmune diseases. The two companies will […]